Hanmi announces positive clinical data on Amozaltan

Published: 2009-05-20 06:56:00

Updated: 2009-05-20 06:56:00

Hanmi Pharm announced positive Phase III data on its new medicine, Amozaltan (amlodipine + losartan), an oral antihypertensive agent, at the local congress hosted by the Korean Society of Nephrology and the Korean Society of Hypertension.

The trial showed that Amozaltan is safe, effective, and well tolerated in the treatment of hypertensiion. Its hypertensive effect of is comparable or supe...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.